❌

Reading view

12 Symptoms ENT Doctors Say Never to Ignore

—Photo-Illustration by Chloe Dowling for TIME (Source Images: PM Images/Getty Images, Plume Creative/Getty Images (2))

You might see an ear, nose, and throat (ENT) doctor for recurring sinus infections. Someone else might see one for a thyroid tumor, a voice that won’t return after a cold, or trouble breathing during sleep. They’re all within an ENT’s purview.

These doctors, formally called otolaryngologists, treat conditions involving the ears, nose, throat, and much of the head and neck. That includes problems affecting your hearing, swallowing, breathing, and voice—and some that require urgent care. “A lot of people will think, ‘Oh yeah, there’s no emergencies at ENT,’ and there absolutely are,” says Dr. Ryan Salvador, an ENT surgeon at Sinus & Snoring Specialists in Austin.

We asked three otolaryngologists what they wish patients wouldn’t ignore.

Sudden hearing loss in one ear

You answer your phone and realize you can barely hear your friend’s voice out of your left ear. Switch to your right side, and everything sounds normal. It’s tempting to assume the muffled ear needs to pop, Salvador says. But an abrupt change in hearing can be a medical emergency.

One possibility is sudden sensorineural hearing loss, which affects the inner ear. Salvador knows how easily it can be mistaken for something else: His father went to urgent care and was told he had fluid behind his eardrum. By the time he saw an ENT, about eight weeks had passed. “He’s completely deaf in that ear now,” Salvador says.

An ENT can examine the ear and arrange a hearing test to find out what’s causing the loss. If it is sudden sensorineural hearing loss, steroids may help—but, as Salvador puts it, “the earlier the better.” Seek medical care immediately if you suddenly lose hearing, even if your ear just feels full or you’ve recently had a cold.

A neck lump that doesn’t hurt

You might discover it while shaving, when your razor passes over a spot that suddenly isn’t smooth. Or perhaps you notice an unfamiliar bump in the mirror. Because it doesn’t hurt, you decide it can’t be that serious.

Dr. Arnbjorn Toset, the director of head and neck surgery at Good Samaritan University Hospital and Catholic Health in New York, hears that reasoning from patients: “Doctor, it’s not hurting me. I don’t have any symptoms.” But pain isn’t a reliable way to judge a neck lump. It might be an enlarged lymph node, a thyroid nodule, or a growth in a salivary gland. But some lumps are cancerous.

Dr. Shaun Desai, chair of otolaryngology at New York Medical College and Westchester Medical Center in New York, recalls a medical student who assumed his lump was related to a cold. “For eight months he sat on this lump in his neck,” Desai says. It turned out to be a salivary gland tumor. If a new lump has no clear explanation or is still there after two weeks, make an appointment.

A sore throat that keeps getting worse

A sore throat is hardly unusual. One that progresses from “this hurts” to “I can barely swallow” is another matter. Salvador pays particular attention when the pain keeps worsening and you’re also having trouble opening your mouth or your voice sounds muffled. “You talk like you’ve got a hot potato in your mouth,” he says.

Those changes can signal an abscess—a pocket of pus that forms around a tonsil. “These can be life threatening,” Salvador says. If swelling makes it difficult to breathe, seek emergency care. Worsening throat pain with trouble swallowing, opening your mouth, or speaking normally also warrants prompt evaluation.

Your partner says you stop breathing at night

Your partner hears you snoring. Then, suddenly, nothing. After a pause, you gasp and start breathing again. By morning, you may have no idea it happened.

The snoring may be what your partner complains about. Desai wants to know about the silence. “The bigger worry is, does your partner kind of stop breathing for a couple of seconds?” he says. Repeated pauses can be a sign of obstructive sleep apnea, in which the airway narrows or closes during sleep. You might wake up exhausted despite spending the whole night in bed. Untreated sleep apnea can also contribute to high blood pressure; Desai worries about people who become so sleepy during the day that they struggle to stay awake while driving.

Tell your doctor about the pauses, gasping, and any daytime sleepiness. A sleep study can show whether apnea is the cause. As Desai puts it, “Apnea is the bigger question, and that can be dangerous if not treated.”

Swelling around an eye during a sinus infection

Sinus pressure can make the area around your eyes ache. What Salvador doesn’t want you to chalk up to ordinary sinus misery is new swelling around an eye—especially if the area is red or your vision changes.

“The only thing that separates the sinus cavity from the eye is a very thin plate of bone,” he says. Rarely, an infection spreads into the tissues around the eye. Salvador has treated patients whose infections formed pockets of pus that had to be drained to protect their vision.

Get urgent medical attention for a newly swollen eye during a sinus infection. If you develop double vision or have trouble moving the eye, seek emergency care. Don’t wait for those symptoms to appear: Double vision is “a pretty late sign,” Salvador says.

Swelling under your jaw when you eat

Halfway through a meal, you notice a tender bump beneath your jaw. It settles down later—then returns the next time you eat.

Toset says that pattern can point to a blocked salivary gland. Eating triggers saliva production, but a stone can keep the saliva from draining, causing the gland to swell. It may also become painful or red.

If it keeps happening, have it examined. Toset says the cause is often benign, but an exam and sometimes imaging can distinguish a stone from another problem with the gland. If the swelling keeps returning, have the gland checked—even if it goes down between meals 

A voice that won’t come back

You talked all weekend. You recently had a cold. Of course your voice sounds rough—or maybe it’s become oddly breathy, and you can’t project the way you used to. These are reasonable explanations for a temporary change, Desai says. They become less reassuring when your voice doesn’t recover.

Salvador remembers a teacher who was struggling to speak loudly enough for her class. “I can’t project,” she told him. When he examined her, he discovered that one of her vocal cords wasn’t moving properly because of a thyroid tumor. Persistent hoarseness can have other explanations, including irritation or a benign growth, but an ENT needs to look to find out.

If hoarseness lasts four weeks, see an ENT—sooner if you smoke or have other concerning symptoms. The doctor may pass a small camera through your nose to look at your vocal cords. If that sounds daunting, Desai says the office exam “just takes a minute or two.”

Dentures that suddenly don’t fit comfortably

Your dentures fit fine last month. Now they rub the same spot every time you put them in, or they don’t sit quite right. You might need an adjustment—or someone to look at what’s going on underneath.

Toset says new discomfort may draw your attention to “a little ulcer on the gum line.” Rubbing can cause a sore, but a growth in the mouth can also change how dentures fit. That’s one possible sign of oral cancer, though there are other explanations.

Ask your dentist to examine the tissue beneath the denture, especially if a sore hasn’t healed after two weeks. They can check what’s changed before adjusting the fit.

A nosebleed that won’t stop

Most nosebleeds start near the front of the nose and stop with pressure. A bleed that starts farther back can be harder to control. The blood vessels there can “pump and pump and pump,” Salvador says, and blood may run down the back of your throat. Doctors call this a posterior nosebleed.

If your nose starts bleeding, lean forward and pinch its soft part with steady pressure for 15 minutes. If the bleeding is heavy or won’t stop, or you feel weak or lightheaded, seek emergency care.

A nosebleed that does stop can still be worth investigating if it keeps coming back. Salvador remembers a man in his 30s who had consistent nosebleeds for about six months before an examination revealed a tumor inside his nose. That’s an uncommon cause, but a good reason to tell your doctor about repeated bleeding—especially if it keeps happening on the same side.

Ear pain when nothing seems wrong 

Your ear hurts, so you probably have an ear infection, right? Not necessarily. Sometimes an examination turns up nothing wrong with the ear itself. Nerves in the head and neck carry a signal from somewhere else, and sometimes, “your brain is tricking you” about where it started, Toset says.

The source might be your jaw joint, which sits just in front of your ear. Less commonly, it could be a problem in your throat or at the base of your tongue. If the pain persists despite a normal ear exam, ask your doctor what else should be checked—especially if it hurts to swallow or you’ve noticed a lump in your neck.

One nostril that stays blocked

Colds and allergies can make your whole nose miserable. A blockage that sticks around on just one side gets Desai’s attention. “When you can’t breathe out of one nostril, it’s always a little more concerning,” he says.

The explanation might be a deviated septum, but a growth inside the nose or sinuses can also block one side. Desai worries about the delay when people tell themselves, “Oh, it’s a cold,” or “I just have a bloody nose.” If the blockage outlasts what seems like an ordinary cold—especially if that side also bleeds repeatedly—have it examined.

A sore on your tongue that won’t heal

Most small mouth sores clear up within a week or two. Toset is more concerned about one that stays put, grows, or becomes increasingly painful—particularly on the side of the tongue.

He remembers seeing a young woman in the emergency room on a Friday night. She had developed swelling in her neck, and the doctors who called Toset thought it might be an abscess. During his examination, he noticed a sore on the side of her tongue. She’d seen dentists and other specialists, and earlier biopsies had come back benign, but the sore had persisted for about six months.

“I had a biopsy. Biopsy was negative, so I left it alone,” Toset recalls her telling him. He examined the sore and grew concerned. “I had to break it to her,” he says: “I think you have tongue cancer.” Another biopsy confirmed it; the swelling in her neck was where the cancer had spread.

A reassuring biopsy shouldn’t be the end of the conversation if the sore is still there. Any mouth sore that hasn’t healed after two weeks should be evaluated, according to the American Academy of Otolaryngology–Head and Neck Surgery.

“I’d rather see someone early on in the process where I can pick up on something that is possibly benign or an early type of cancer,” Toset says, than see them after a delay that makes treatment more difficult.

  •  

What to Know About the Blood Clot Sidelining Jalen Hurts

Jalen Hurts of the Philadelphia Eagles looks on during the NFL match between Philadelphia Eagles and Jacksonville Jaguars at Tottenham Hotspur Stadium on October 11, 2026 in London. —DeFodi Images—Getty Images

For an NFL quarterback, a sore calf might seem like an unsurprising consequence of getting hit by a cleat. In Jalen Hurts’ case, an ultrasound revealed something else: a superficial blood clot.

The Philadelphia Eagles quarterback was struck in the calf during an Oct. 4 game and sought treatment four days later, according to a statement from the team. An ultrasound in London revealed the clot, but doctors cleared him to play in the team’s game there the next day.

Then, a follow-up ultrasound Wednesday night revealed “movement in the small blood clot.” The Eagles announced Thursday that Hurts would miss Sunday’s game against the Carolina Panthers while the team determines his treatment.

What makes a clot superficial—and when does it become dangerous? We asked doctors to explain.

What’s the difference between a superficial clot and deep vein thrombosis?

To understand blood clots, picture a road map. Your deep veins run within the muscles of your arms and legs, carrying most of the blood returning from your limbs to your heart. Superficial veins sit closer to the surface, just underneath the skin and in the tissue beneath it. Connecting veins bridge the two systems.

“You have a really well interconnected network of veins,” says Dr. William Shutze, a vascular surgeon at Texas Vascular Associates in Dallas and vice president of the Society for Vascular Surgery (who was not involved in Hurts’ care). Think of it as “a very well developed road and highway system,” with multiple routes to get where you need to go.

When a clot blocks one route, blood can take a detour through other veins.

A superficial clot forms in one of the veins near the skin. The area can become red, warm, and tender. “It’s usually very uncomfortable,” Shutze says. Some develop in varicose veins; others form where a needle or IV has irritated a vein.

You can sometimes feel the affected vein beneath your fingers. “It’s like a pencil underneath the skin, or a knot,” says Dr. Stephan Moll, a hematologist and professor of medicine at the University of North Carolina who runs an Athletes and Blood Clots Clinic (who was not involved in Hurts’ care).

Deep vein thrombosis involves a clot farther inside the body. Its symptoms can be more widespread—the whole calf or ankle might become swollen and painful, Moll says. You can’t feel the deep vein itself.

Many superficial clots stay put and get better without blood thinners. But sometimes, a clot grows into one of the deeper veins. A piece can then break off and travel to the lungs, causing a potentially life-threatening complication called a pulmonary embolism.

Doctors use ultrasound to assess the clot and check for deep-vein involvement, Shutze says. They’re particularly concerned about superficial clots longer than 5 centimeters or within 3 centimeters of where a superficial vein joins a deep one.

The Eagles haven’t specified those details. And “movement” isn’t precise enough to establish what happened. “That’s not a term we use in clinical practice,” Moll says. It could describe a clot growing or extending; it doesn’t, by itself, establish that a piece broke loose or reached the lungs.

How do these clots happen—and how are they treated?

Being in excellent shape doesn’t make someone immune to a blood clot. An injury can damage a vein, while prolonged inactivity slows blood flow. Surgery, certain inherited clotting disorders, cancer, and pregnancy can also increase risk, says Dr. Alina Mitina, an emergency medicine physician at Hackensack University Medical Center in New Jersey (who was not involved in Hurts’ care).

Veins near the skin have less cushioning when someone takes a hit. “The deeper veins are protected,” Shutze says, although a severe impact can injure those, too.

A clot can form within hours of an injury or develop over several days, he adds. If your leg already hurts from getting hit, you might not realize there’s another reason it’s sore.

Travel can add another risk: Sitting through a long flight or car ride means the legs aren’t moving as much, slowing blood flow. 

Some superficial clots can be managed with warm compresses, anti-inflammatory medication, elevation, and monitoring. Others need blood thinners to help keep the clot from growing—even if it hasn’t reached a deep vein.

If blood thinners are needed, treatment is usually temporary, Moll says, often lasting several weeks.

That doesn’t necessarily mean spending recovery on the couch. “We like them to be active because we want to keep the blood flowing,” Shutze says.

Getting up for a walk, of course, is different from getting tackled. Shutze worries about athletes taking another hit where they already have a clot. Blood thinners add another concern: An injury that causes bleeding can become much more dangerous when blood doesn’t clot as readily.

In football, “you have constant significant contact,” Moll says, which raises the risk of serious bleeding, including inside the head or muscles.

What symptoms shouldn’t you ignore?

Athletes are used to being sore. “They often minimize clinical symptoms, completely understandably, because they don’t want to be taken off the roster,” Moll says.

Pay attention when discomfort feels different, persists, or worsens. Pain, swelling, discoloration, and warmth can signal a clot. Mitina says patients sometimes describe tightness in the leg; redness around a superficial clot can resemble an infection.

If you think you might have a superficial clot, “don’t ignore it,” Shutze says. Have a doctor check it out rather than assuming it’s a bruise or muscle strain.

Unexplained shortness of breath, chest pain, coughing up blood, or fainting require emergency care because they can signal a pulmonary embolism. Moll also flags an unexplained cough and fast heart rate as possible warning signs.

And getting checked once doesn’t mean you should brush off symptoms that persist or worsen. “If something feels weird or symptoms aren’t getting better, always return to the ER,” Mitina says. “You know your body best.”

  •  

Why your health insurance is dropping GLP-1 coverage

GLP-1 pens

The promise of GLP-1 drugs has always depended on people being able to afford them. These drugs still cost hundreds of dollars per month if you’re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them — unless their health insurance covers it.

For a while, the trend lines for GLP-1 insurance coverage were positive. As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. Over the summer, Medicare launched a new $50-per-month prescription program. The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system.

At least that’s how things appeared earlier this year. But now, private plans are pulling back from GLP-1 coverage. People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health.

The dilemma reveals one of the structural flaws in American healthcare. For working-age adults, your insurance depends on your job. Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term — but there is a strong incentive to minimize short-term costs as much as possible. It’s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person’s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems, improving their health and saving all of us money as they get older.

“An employer or an insurer making coverage decisions doesn’t necessarily care if they’re saving Medicare money,” said Dan Sacks, a healthcare economist at the University of Wisconsin-Madison. “That’s a classic problem with the American health insurance system, and it’s certainly salient here.”

This mismatch between what’s good for people’s health and what’s good for the corporate bottom line has long been one of the underlying flaws in the US health system. Now access to GLP-1 drugs is shrinking just as these drugs were starting to make a real dent in the US obesity crisis. The stakes couldn’t be higher.

Why employer-sponsored health plans are suddenly dropping GLP-1 coverage

From the beginning, insurance coverage was the big question hanging over GLP-1s and their potential to revolutionize US healthcare. But recently, it looked like we’d turned a corner.

When I attended the Aspen Ideas: Health festival over the summer, pharmaceutical reps seemed visibly relieved that GLP-1 coverage had been picking up among private insurers. In 2026, about two out of every three employer-sponsored plans were covering some of these drugs for weight management, up from about 20 percent just the year before.

“They’re recognizing that this is an investment in their workforce,” said Laura Steele, who leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo. “Yes, there is a budget, and there is a benefit design that every employer has. That’s real. That’s not going away. But they’re also recognizing the overall cost that they’re experiencing by not dealing with this too.”

But as employers and private insurers make coverage decisions for next year, they are suddenly pulling back. At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to one survey by the Business Group on Health — and that number may still increase. A Mercer survey of large employers found that 6 percent had dropped coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it. A separate report from the Health Policy Commission in Massachusetts found that the number of commercially insured people in the state taking a GLP-1 drug had fallen by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off. 

Some of the biggest brands in the US are reportedly eliminating or reducing their coverage: PepsiCo, Starbucks, and Lowe’s among them. And their reasons are simple: It’s too expensive. The drugs still carry a high net price tag — $600 or more for a 30-day supply — and potential demand is high (two in every five American adults have obesity). 

When a lot of people start taking an expensive medication all at once, it’s going to raise costs for employer insurance plans — and they have to figure out how to adapt. Insurers set premiums at the start of each year, based on how many people are on the plan and how much healthcare they are expected to need. But if those estimates are off — say, if more people take an expensive GLP-1 drug than the insurer expected — they have to offset those costs somehow, and raising premiums the following year is a common solution. According to one estimate, premiums are projected to grow by 5 to 13 percent due to GLP-1 costs — and the burden of paying those higher premiums is likely to fall on the workers. The employer can also try to limit GLP-1 use by, for example, asking workers to pay more out of pocket for these drugs; according to Mercer, 27 percent of large US employers instituted some kind of utilization controls for GLP-1 drugs over the past year or plan to next year.

They also have the option to simply stop covering these drugs for weight loss altogether — and that’s the route more and more of them are deciding to take. The abrupt reversal has even caught economists like Sacks off guard.

3 big reasons employer health plans are dropping GLP-1 coverage

  • Employers aren’t invested in people’s long-term health: As Americans switch jobs more often, companies want to cut short-term costs.
  • GLP-1 prices are still high, upward of $600 per month per person for insurers.
  • A lot of people are eligible to take them for weight loss; two in five US adults have obesity.

“I was surprised that anyone would do an about-face because I thought they understood the trade-offs well,” Sacks said. “My guess is that it turned out to be more expensive than they anticipated: Take-up is higher, and possibly more people are sticking with it. That’s one reason that you might not want to continue to offer it.”

For employers, the short-term costs of covering a drug often outweigh the long-term benefits that medication may confer, at least from the employer’s POV. One analysis — notably produced by Blue Cross Blue Shield Kansas — concluded that covering GLP-1s for weight loss increased average employee health costs by $7,000 in the first year and another $4,200 in the second, largely due to the cost of the drugs themselves. And yet at the same time, there were no decreases in obesity-related medical events in that time period. Another study from Sacks and his colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not lead to any cost savings over five years.

So in the short term, these employers are arguably making an economically rational decision — but one that may still come at their employees’ expense. “I’m completely screwed,” said one person on Reddit about Cigna’s plans to drop GLP-1 coverage for their own employees. They’re looking at at least $300 for one month’s supply at cash prices. 

They weren’t alone either: “I’m devastated,” said another person, commenting on Starbucks’s decision to stop covering GLP-1 drugs. They said they had an autoimmune condition that had made it difficult to lose weight — until this new class of medicines came along.

Where GLP-1 coverage goes from here

How could we end up here, where it makes good business sense for companies to make a decision that could potentially harm their workers’ health in the long term? It is at least in part a result of the haphazard way the US has ended up insuring people.

When employer-sponsored insurance started to arise in the mid-20th century, eventually becoming the primary way to cover the working-age population, people tended to stay at the same job for a long period of time. In theory, there was a synergy: Companies wanted their workers to stay productive, and so it was worth it for the company to invest in their long-term health via their insurance benefits. And research has found that people who stay with the same company — and the same insurance plan — tend to have better health than those who switch a lot.

But these days, people change jobs all the time or work various gigs to piece together an income. You probably don’t expect to stay at your job for 10 years — and your employer doesn’t expect you to either. Instead, they want to keep their own costs as low as possible in the short term. This leads them to cut GLP-1 coverage, even though doctors do believe that people could benefit tremendously long term from the weight loss these drugs help them achieve and all of its potential health benefits. 

“There are very real health benefits of these drugs,” Sacks told me. “The fact that we don’t find offsets or they’re even more expensive than we thought doesn’t necessarily mean that we shouldn’t cover them.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here.

In theory, the market is supposed to fix the price problem: Drug companies get a period of exclusivity for the drugs they develop, and then, once that time elapses, cheaper generic versions can come onto the market. But generic semaglutide won’t be available in the US until at least 2031 — and for some versions, the generic competitors aren’t going to debut until the 2040s. Offering GLP-1 coverage could become a competitive advantage for employers, a perk they can offer to entice potential workers as part of their benefits package.

Beyond that, though, the path to more affordable GLP-1s is not immediately obvious right now. A lot of people are already willing to pay cash for these drugs — and that may continue as long as people can afford to do it. But with inflation still steadily rising, these drugs could slip out of reach for more and more Americans.

The government could get involved, but, for now, the federal government’s negotiating authority only covers Medicare, not the private plans that are dropping coverage. Serious healthcare reform is probably off the table until at least 2028, and then only if Democrats win both Congress and the White House and decide to make a healthcare package their legislative priority.

But the lesson of these recent developments is that, at some point, the US may have to look seriously at the underlying problem creating this mess in the first place. A patchwork method of insuring people that privileges short-term cost-cutting over people’s long-term health isn’t a real healthcare system.

  •  
❌